UBS Maintains Buy on Boston Scientific, Lowers Price Target to $105

Benzinga Newsdesk www.benzinga.com Negative 68.4%

Neg 68.4% Neu 0% Pos 0%

UBS analyst Danielle Antalffy maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $120 to $105.